ArticleEuropean journal of nuclear medicine and molecular imaging2023
Extended therapy with [
Article in European journal of nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Evaluating Xerostomia as a side effect of [European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Influence of increased injected activities up 9.0 GBq [EJNMMI physics · 2026Article
- PSMA-RECAP: [Frontiers in oncology · 2026Article
- Lesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA Radioligand vs. Radium- 223-naïve mCRPC patients.European journal of nuclear medicine and molecular imaging · 2025Article
- Article
- Development of a CT-less SPECT Acquisition Protocol for Kidney Dosimetry inMolecular imaging and biology · 2025Article
- Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.European journal of nuclear medicine and molecular imaging · 2025Article
- Cancer-control outcomes with [Theranostics · 2025Article
- Efficacy and safety of rechallenge with [European journal of nuclear medicine and molecular imaging · 2024Article
- Efficacy and safety of rechallenge [European journal of nuclear medicine and molecular imaging · 2024Observational
- Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [European journal of nuclear medicine and molecular imaging · 2024Article
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
- Lesion Dosimetry for [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Impact of [Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe currently used scheme for radioligand therapy (RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC) consists of 4-6 cycles of 6.0-7.4 GBq [
methodsTwenty-six patients with high-volume residual tumor burden (according to CHAARTED) after standard RLT with [
resultsFurther PSA decline of 33 ± 28% during the extended treatment was observed in 21/26 (81%) patients, whereas 5/26 (19%) patients showed a PSA increase; correspondingly in 11/21 patients with an initial response (PR or SD) to extended cycles, treatment was discontinued due to progressive disease, whereas six (23%) patients achieved low-volume residual disease. Two (8%) patients died without showing progression, and two (8%) patients are still under therapy. The median progression-free survival was 19 (95% CI: 15-23) months, and the overall survival was 29 (95% CI: 18-40) months. Grade ≥ 3 hematological toxicities occurred in 4/26 (15%) patients during treatment extension, and nephrotoxicity (grade ≥ 3) was observed in 1/26 (4%) patient during the follow-up.
conclusionExtended radioligand therapy is a feasible treatment option in patients with high-volume residual tumor after the completion of standard treatment with six cycles of [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.